CEEGOG

ENGOT-EN2 / DGCG

A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.

Trial Number
NCT01244789 (ClinicalTrials.gov ID)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-EN16/ NOGGO S22/ Expression XI

IMPROVE - International Survey for Endometrial Cancer patients: perspective and expectation on therapy and quality of life

Trial Number
DRKS00025954
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

MK-2870-005-ENGOT-en23

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy

Trial Number
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

C93GOG-3064 ENGOT-en15

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

Trial Number
NCT05173987 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

GLORIOSA

Randomized, multicenter, open-label, phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab

Trial Number
NCT05445778 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-ov72/ROSELLA

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Trial Number
NCT05257408 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-ov51/NItCHE/MITO33

Randomized phase III trial on NIraparib-dostarlimab vs physiscian’s choice CHEmotherapy in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer

Trial Number
NCT04679064 (ClinicalTrials.gov Identifier)
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

SALVOVAR

A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery

Trial Number
Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
Subscribe to CEEGOG